Early Access — free while we kick the tires
EdgarHawk

MILBY RANDY

CEO

Director Officer
1 filing analyzed · 1 company · Latest 2024-12-20

Companies

Company Buys Sells Direction
Tharimmune, Inc. CNTN 1 0 Net buying

Activity

December 2024
2024-12-20 Tharimmune, Inc. CNTN
high
Buy
4,600 shares
$9,752
Significance 8/10

CEO Randy Milby bought 4,600 shares at $2.12 on 2024-12-19; stock now -74.2% from 52-week high, company posted -$3.8M net income.

CEO Randy Milby purchased 4,600 shares (35.6% increase to holdings of 17,534 shares) at $2.12 on 2024-12-19, a deliberate accumulation in a deeply distressed position: the stock trades at $2.07, down 74.2% from its 52-week high of $8.02, and the company reported a net loss of $3,795,852.00 against a $3.1M market cap. His prior same-ticker buys at this company in late 2023 exhibited exceptional timing, with the 2023-12-15 purchase returning +1219.9% over 30 days and +1000.4% over 90 days, and the 2023-11-30 purchase returning +663.5% over 30 days and +507.5% over 90 days—both well-timed at the 90-day mark. However, his more recent October 2024 purchases at the same ticker have only posted modest 15–17% 30-day gains with no 90-day outcome yet measurable, suggesting the earlier outsized gains have not repeated. The purchase occurs in a sharply declining 30-day (-17.2%) and 90-day (-27.1%) window, and the company's negative profitability signals operational distress rather than a temporary valuation trough. While his cross-ticker track record shows 100% win rate over 90 days with +754.0% average return across 5 prior buys, that same-ticker pattern has compressed significantly in recent months, warranting scrutiny of whether current fundamentals justify further accumulation.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access